Абстрактный

Impact of Sacubitril/Valsartan on Patient Outcomes in Chronic Heart Failure

Eyubova UA, Rahimova G, Bakhshiyev MM

Background: Chronic Heart Failure (CHF) remains one of the most important problems in cardiology, despite the availability of various modern diagnostic methods and a number of advances in treatment. This is due to its widespread use, lowering the quality of life of patients, as well as high rates of recurrent decompensation and death. Despite the optimal use of modern treatments based on proven medical principles, the disease still has a high morbidity and mortality rate.

Aim: The aim of our study was to evaluate the conservative treatment which pathogenetic complementarity with the inclusion of a combination of sacubitril/valsartan in the treatment of patients with chronic heart failure with a comparison with device therapy of chronic heart failure.

Materials and Methods: The study included 64 patients over the age of 38 suffering from Chronic Heart Failure (CHF) (45 men, 19 women, 59.5 ± 0.9 years of age). Patients were divided into basic and control groups. 33 patients were included in the main group. In the main group, patients received sacubitril/valsartan twice daily in addition to the classic conservative treatment of CHF. The control group included 31 patients who underwent CRT surgery and classic conservative treatment without of sacubitril/valsartan. During the study, the clinical performance of patients before and after 6 months of treatment, the results of BNP tests, the results of a 6-minute walking test were compared.

Conclusion: Evaluation of the results of examinations of patients after 6 months revealed more positive changes in the indicators of the majority of patients in the main group (especially on functional class) than in 6 months ago.